SIAIS562055 is an experimental anticancer drug which acts as a proteolysis targeting chimera (PROTAC) against the protein SOS1, acting by targeting this protein for destruction by cell maintenance enzymes. It was derived from the selective SOS1 inhibitor BI-3406. It is being researched for the treatment of some forms of leukemia as well as other cancers.